186 related articles for article (PubMed ID: 34986965)
1. Does Prior Cancer Have an Influence on the Survival Outcomes of Patients with Localized Pancreatic Neuroendocrine Tumors?
Wang L; Li G; Bing YT; Tian ML; Wang HY; Yuan CH; Xiu DR
Chin Med Sci J; 2021 Dec; 36(4):284-294. PubMed ID: 34986965
[TBL] [Abstract][Full Text] [Related]
2. Impact of a Prior Nonpancreatic Malignancy on Survival Outcomes of Patients With Stage IV Pancreatic Neuroendocrine Tumor: A Population-Based and Propensity Score Matching Study.
Li G; Tian ML; Bing YT; Yuan CH; Xiu DR
Pancreas; 2020 Sep; 49(8):1090-1098. PubMed ID: 32833943
[TBL] [Abstract][Full Text] [Related]
3. Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database.
Assi HA; Mukherjee S; Kunz PL; Machiorlatti M; Vesely S; Pareek V; Hatoum H
Oncologist; 2020 Feb; 25(2):e276-e283. PubMed ID: 32043766
[TBL] [Abstract][Full Text] [Related]
4. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study.
Kim H; An S; Lee K; Ahn S; Park DY; Kim JH; Kang DW; Kim MJ; Chang MS; Jung ES; Kim JM; Choi YJ; Jin SY; Chang HK; Cho MY; Kang YK; Kang M; Ahn S; Kim YW; Hong SM;
Cancer Res Treat; 2020 Jan; 52(1):263-276. PubMed ID: 31319641
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Survival Following Surgical Resection for Small Nonfunctional Pancreatic Neuroendocrine Tumors.
Sugawara T; Rodriguez Franco S; Kirsch MJ; Colborn KL; Ishida J; Grandi S; Al-Musawi MH; Gleisner A; Del Chiaro M; Schulick RD
JAMA Netw Open; 2023 Mar; 6(3):e234096. PubMed ID: 36976561
[TBL] [Abstract][Full Text] [Related]
7. The Eighth Edition of the American Joint Committee on Cancer Distant Metastases Stage Classification for Metastatic Pancreatic Neuroendocrine Tumors Might Be Feasible for Metastatic Pancreatic Ductal Adenocarcinomas.
Wen J; Chen J; Liu D; Xu X; Fan M; Zhang Z
Neuroendocrinology; 2020; 110(5):364-376. PubMed ID: 31357196
[TBL] [Abstract][Full Text] [Related]
8. Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival.
Kim JY; Lee SH; An S; Kim SJ; Sung YN; Song KB; Hwang DW; Kim SC; Hong SM
Virchows Arch; 2018 May; 472(5):739-748. PubMed ID: 29666945
[TBL] [Abstract][Full Text] [Related]
9. Survival Benefit of Surgical Resection for Pancreatic Neuroendocrine Tumors With Oligometastatic Liver Metastasis: A Retrospective and Propensity Score-Matching Analysis.
Yang Z; Liang J; Leng K; Shi G
Front Oncol; 2022; 12():903560. PubMed ID: 35847865
[TBL] [Abstract][Full Text] [Related]
10. Primary site surgery for elderly patients with distant metastatic pancreatic neuroendocrine tumor: to do or not to do?
Zhang J; Peng CS; Tian YH
Clin Interv Aging; 2019; 14():1419-1432. PubMed ID: 31496669
[TBL] [Abstract][Full Text] [Related]
11. Reappraisal of a 2-cm Cutoff Size for the Management of Nonfunctional Pancreatic Neuroendocrine Tumors: A Population-Based Study.
Yang Z; Zhang D; Shi G
Front Endocrinol (Lausanne); 2022; 13():928341. PubMed ID: 35923628
[TBL] [Abstract][Full Text] [Related]
12. Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors.
Krauss T; Ferrara AM; Links TP; Wellner U; Bancos I; Kvachenyuk A; Villar Gómez de Las Heras K; Yukina MY; Petrov R; Bullivant G; von Duecker L; Jadhav S; Ploeckinger U; Welin S; Schalin-Jäntti C; Gimm O; Pfeifer M; Ngeow J; Hasse-Lazar K; Sansó G; Qi X; Ugurlu MU; Diaz RE; Wohllk N; Peczkowska M; Aberle J; Lourenço DM; Pereira MAA; Fragoso MCBV; Hoff AO; Almeida MQ; Violante AHD; Quidute ARP; Zhang Z; Recasens M; Díaz LR; Kunavisarut T; Wannachalee T; Sirinvaravong S; Jonasch E; Grozinsky-Glasberg S; Fraenkel M; Beltsevich D; Egorov VI; Bausch D; Schott M; Tiling N; Pennelli G; Zschiedrich S; Därr R; Ruf J; Denecke T; Link KH; Zovato S; von Dobschuetz E; Yaremchuk S; Amthauer H; Makay Ö; Patocs A; Walz MK; Huber TB; Seufert J; Hellman P; Kim RH; Kuchinskaya E; Schiavi F; Malinoc A; Reisch N; Jarzab B; Barontini M; Januszewicz A; Shah N; Young WF; Opocher G; Eng C; Neumann HPH; Bausch B
Endocr Relat Cancer; 2018 Sep; 25(9):783-793. PubMed ID: 29748190
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study.
Zhang P; Li YL; Qiu XD; Luo J; Shi YF; Sun YL; Su F; Qi ZR; Tan HY
World J Surg Oncol; 2019 Apr; 17(1):66. PubMed ID: 30975157
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic acinar cell carcinomas and mixed acinar-neuroendocrine carcinomas are more clinically aggressive than grade 1 pancreatic neuroendocrine tumours.
Kim JY; Brosnan-Cashman JA; Kim J; An S; Lee KB; Kim H; Park DY; Jang KT; Oh YH; Hruban RH; Heaphy CM; Hong SM
Pathology; 2020 Apr; 52(3):336-347. PubMed ID: 32111396
[TBL] [Abstract][Full Text] [Related]
15. A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors.
Wang WQ; Zhang WH; Gao HL; Huang D; Xu HX; Li S; Li TJ; Xu SS; Li H; Long J; Ye LY; Wu CT; Han X; Wang XH; Liu L; Yu XJ
J Gastroenterol; 2021 Apr; 56(4):395-405. PubMed ID: 33742253
[TBL] [Abstract][Full Text] [Related]
16. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.
Hackeng WM; Brosens LAA; Kim JY; O'Sullivan R; Sung YN; Liu TC; Cao D; Heayn M; Brosnan-Cashman J; An S; Morsink FHM; Heidsma CM; Valk GD; Vriens MR; Nieveen van Dijkum E; Offerhaus GJA; Dreijerink KMA; Zeh H; Zureikat AH; Hogg M; Lee K; Geller D; Marsh JW; Paniccia A; Ongchin M; Pingpank JF; Bahary N; Aijazi M; Brand R; Chennat J; Das R; Fasanella KE; Khalid A; McGrath K; Sarkaria S; Singh H; Slivka A; Nalesnik M; Han X; Nikiforova MN; Lawlor RT; Mafficini A; Rusev B; Corbo V; Luchini C; Bersani S; Pea A; Cingarlini S; Landoni L; Salvia R; Milione M; Milella M; Scarpa A; Hong SM; Heaphy CM; Singhi AD
Gut; 2022 May; 71(5):961-973. PubMed ID: 33849943
[TBL] [Abstract][Full Text] [Related]
17. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate.
McCall CM; Shi C; Cornish TC; Klimstra DS; Tang LH; Basturk O; Mun LJ; Ellison TA; Wolfgang CL; Choti MA; Schulick RD; Edil BH; Hruban RH
Am J Surg Pathol; 2013 Nov; 37(11):1671-7. PubMed ID: 24121170
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic and prognostic significance of multiple hormone expression in pancreatic neuroendocrine tumors.
Kim JY; Kim MS; Kim KS; Song KB; Lee SH; Hwang DW; Kim KP; Kim HJ; Yu E; Kim SC; Jang HJ; Hong SM
Am J Surg Pathol; 2015 May; 39(5):592-601. PubMed ID: 25602797
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex.
Larson AM; Hedgire SS; Deshpande V; Stemmer-Rachamimov AO; Harisinghani MG; Ferrone CR; Shah U; Thiele EA
Clin Genet; 2012 Dec; 82(6):558-63. PubMed ID: 22035404
[TBL] [Abstract][Full Text] [Related]
20. Surgical Treatment of Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: An NCDB Analysis.
Kaslow SR; Vitiello GA; Prendergast K; Hani L; Cohen SM; Wolfgang C; Berman RS; Lee AY; Correa-Gallego C
Ann Surg Oncol; 2022 Jun; 29(6):3522-3531. PubMed ID: 35246811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
